

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/507,928 #6804
				Filing Date	March 19, 2003
				First Named Inventor	Ralph P. Braun
				Art Unit	1633
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	HO-P03173US0-10505259

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/IP/	AA	US-5,958,895	Sep. 28, 1999	Pachuk et al.	
/IP/	AB	US-2003/0139364-A1	Jul. 24, 2003	Kreig et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/IP/	BA	WO 1998/50567	Nov. 12, -1998	Abbott Laboratories		
/IP/	BB	WO 2001/46228	Jun. 28, 2001	Glaxo Group Limited		
/IP/	BC	WO 2005/025614	Mar. 24, 2005	Glaxo Group Limited		


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
/IP/	CA	"Interferon-gamma as adjuvant in immunocompromised mice," Immunology, Abstract of Heath AW, August 1989, 67(4): 520-4.				
	CB	"Interferon-gamma potentiates antibody affinity in mice with a genetically controlled defect in affinity maturation," Clin Exp Immunol, Abstract of Holland GP, November 1990, 82(2): 221-226.				
	CC	"Recombinant gamma interferon is a potent adjuvant for a malaria vaccine in mice", Clin Exp Immunol, Abstract of Playfair JH, January 1987, 67(1):5-10.				
	CD	"Specific immune responses of dairy cattle after primary inoculation with recombinant bovine interferon-gamma as an adjuvant when vaccinating against mastitis", Am J Vet Res. Abstract of Pighetti GM, June 1996, 57(6):819-24.				
	CE	XIANG Z., et al., "Manipulation of the immune response to a plasmid-encoded Viral Antigen by Coinoculation with Plasmids Expressing Cytokines", Immunity, Vol. 2, February 1995, pp. 129-135.				
	CF	BAEK, KM et al. "Comparative analysis of effects of cytokine gene adjuvants on DNA vaccination against Mycobacterium tuberculosis heat shock protein 65", Vaccine, 21, May 2003, pp. 3684-3689.				
	CG	HAYASHI, F. et al., "Toll-like receptors stimulate human neutrophil function," Blood, 1 October 2003, Vol. 102, No. 7, pp. 2660-2669.				
	CH	HARRISON, C.J., "Effect of S28463 as an adjuvant for an immunotherapeutic HSV glycoprotein D (gD) DNA vaccine: Reduction of recurrent genital HSV disease in guinea pigs," Abstracts of the 36th ICAAC, page 185.				
	CI	HEMMI, H., et al. "Small anti-viral compounds active immune cells via the TLR7 MyD88-dependent signaling pathway," Nature Immunology, Vol. 3, No. 2, February 2002, pp. 196-200.				
	CJ	JURK, M. et al., "Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848," Nature Immunology, Vol. 3, No. 6, June 2002, page 499.				
/IP/CK		KURT- JONES, E., et al., "Role of Toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF				

Examiner Signature	/Ileana Popa/	Date Considered	11/09/2007
--------------------	---------------	-----------------	------------

25713962.1



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/507,928 #6804
				Filing Date	March 19, 2003
				First Named Inventor	Ralph P. Braun
				Art Unit	1633
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	HO-P03173US0-10505259


		enhances TLR2-mediated interleukin 8 responses in neutrophils," Blood, 1 September 2002, Vol. 100, No. 5, pp. 1860-1868.	
/IP/	CL	LEHNER, T., et al., "The role of $\gamma\delta$ T cells in generating antiviral factors and β -chemokines in protection against mucosal simian immunodeficiency virus infection," Eur. Immunol May 2000, pp. 2245-2256.	
	CM	MILLER, R.L., et al., "Imiquimod applied topically: a novel immune response modifier and new class of drug," International journal of Immuno pharmacology 21, July 1998, pp. 1-14.	
	CN	SAUDER, D., "Immunomodulatory and pharmacologic properties of imiquimod," American Academy of Dermatology, Inc., 2000. pp. S6-S11.	
	CO	SCHEERLINCK, J-P., "Genetic adjuvants for DNA vaccines," Vaccine 19, 2001, pp. 2647-2656.	
	CP	STANLEY, M.A., "Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential," Clinical & Experimental Dermatology, Vol. 27, No. 7, October 1992, pp. 571-577(7).	
	CQ	THOMSEN, L.L., "Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccinations by particle-mediated immunotherapeutic delivery," Vaccine 22, 2004, pp. 1799-1809.	
	CR	ZUBBER, A.K., "Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA," Vaccine 22, 2004, pp. 1791-1798.	
/IP/	CS	BRETT, S., "Strategies to Adjuvanties Particle Mediated Delivery of DNA Immunotherapeutic," Presentation given at meeting in Oxford, March 2006, pp. 1-6.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Ileana Popa/	Date Considered	11/09/2007
--------------------	---------------	-----------------	------------

25713962.1



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0851-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the America Invents Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/507,928
		Filing Date	March 19, 2003
		First Named Inventor	Ralph P. Braun
		Art Unit	1633
		Examiner Name	Not Yet Assigned
Sheet 1 of 2	Attorney Docket Number	HO-P03173US0	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/IP/	A1	US-4,689,338	08-25-1987	Gerster	
	A2	US-4,929,624	05-29-1990	Gerster et al.	
	A3	US-5,238,944	08-24-1993	Wick et al.	
	A4	US-5,266,575	11-30-1993	Gerster et al.	
	A5	US-5,268,376	12-07-1993	Gester	
	A6	US-5,346,905	09-13-1994	Gerster	
	A7	US-5,352,784	10-04-1994	Nikolaides et al.	
	A8	US-5,389,640	02-14-1995	Gerster et al.	
	A9	US-5,395,937	03-07-1995	Nikolaides et al.	
	A10	US-5,482,936	01-09-1996	Lindstrom	
	A11	US-5,494,916	02-27-1996	Lindstrom et al.	
	A12	US-5,525,612	06-11-1996	Gerster	
	A13	US-6,083,505	07-04-2000	Miller et al.	
	A14	US-6,245,776	06-12-2001	Skwierczynski et al.	
	A15	US-20010006950-A1	07-05-2001	Punnonen et al.	
	A16	US-6,323,200	11-27-2001	Gerster et al.	
/IP/	A17	US-6,331,539	12-18-2001	Crooks et al.	
	A18	US-6,558,951	05-06-2003	Tomai et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² -Number ³ -Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/IP/	B1	WO-98/46263	10-22-1998	Lu	
	B2	WO-99/29693	06-17-1999	Lindstrom et al.	
	B3	WO-01/47955	07-05-2001	Hanke et al.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
/IP/	C1	Bryant et al., "Biology and molecular biology of human immunodeficiency virus," <i>Pediatr. Infect. Dis. J.</i> , 11: 390-400, 1992.		
/IP/	C2	Burns et al., "The Imidazoquinolines, Imiquimod and R-848, Induce Functional, but Not Phenotypic, Maturation of Human Epidermal Langerhans' Cells," <i>Clinical Immunology</i> , 94(1): 13-23, 2000.		
/IP/	C3	Deonarain, "Ligand-targeted receptor-mediated vectors for gene delivery," <i>Exp. Opin. Ther. Patents</i> , 8(1): 53-69, 1998.		
/IP/	C4	Dockrell et al., "Imiquimod and resiquimod as novel immunomodulators," <i>Journal of Antimicrobial Chemotherapy</i> , 48: 751-755, 2001.		

Examiner Signature	/Ileana Popa/	Date Considered	11/09/2007
--------------------	---------------	-----------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	10/507,928
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	March 19, 2003
				First Named Inventor	Ralph P. Braun
				Art Unit	1633
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	HO-P03173US0

/IP/	C5	Eck et al., "Gene-Based Therapy," In: <i>Goodman & Goodman's The Pharmacological Basis of Therapeutics</i> , 9th Ed., McGraw-Hill, pp. 77-101, 1996.	
	C6	Gorecki, "Prospects and problems of gene therapy: an update," <i>Expert Opin. Emerging Drugs</i> , 6(2): 187-198, 2001.	
	C7	Greene, "The Molecular Biology of Human Immunodeficiency Virus Type 1 Infection," <i>The New England Journal of Medicine</i> , 324(5): 308-317, 1991.	
	C8	Harrison et al., "Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine," <i>Vaccine</i> , 19: 1820-1826, 2001.	
	C9	Hemmi et al., "Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway," <i>Nature Immunology</i> , 3(2): 196-200, 2002.	
	C10	Johnson, "Molecular Adjuvants and Immunomodulators: New Approaches to Immunization," <i>Clinical Microbiology Reviews</i> , 7(3): 277-289, 1994.	
	C11	Lisiewicz et al., "Therapeutic vaccination for future management of HIV/AIDS," <i>Vaccine</i> , 21:620-623, 2003.	
	C12	Skalka, "Introduction," <i>Advances in Virus Research</i> , Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania, 52: 271-273, 1999.	
	C13	Spruance et al., "Application of a Topical Immune Response Modifier, Resiquimod Gel, to Modify the Recurrence Rate of Recurrent Genital Herpes: A Pilot Study," <i>The Journal of Infectious Diseases</i> , 184: 196-200, 2001.	
	C14	Tang et al., "Genetic immunization is a simple method for eliciting an immune response," <i>Nature</i> , 356: 152-154, 1992.	
	C15	Tomai et al., "Immunomodulating and antiviral activities of the imidazoquinoline S-28463," <i>Antiviral Research</i> , 28: 253-264, 1995.	
	C16	Ulmer et al., "Heterologous Protection Against Influenza by Infection of DNA Encoding a Viral Protein," <i>Science</i> , 259: 1745-1749, 1993.	
	C17	Verma et al., "Gene therapy - promises, problems and prospects," <i>Nature</i> , 389: 239-242, 1997.	
	C18	Wang et al., "Gene inoculation generates immune responses against human immunodeficiency virus type 1," <i>Proc. Natl. Acad. Sci. USA</i> , 90: 4156-4160, 1993.	
/IP/	C19	Yao et al., "Virus-like particle and DNA-based candidate AIDS vaccines," <i>Vaccine</i> , 21: 638-643, 2003.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Ileana Popa/	Date Considered	11/09/2007
--------------------	---------------	-----------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 17, 2004 (use as many sheets as necessary)				Complete if Known	
				Application Number	Unassigned, National Stage of PCT/GB03/01213
				Filing Date	9/17/2004 10/507928
				First Named Inventor	Ralph Patrick Braun
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	036481-0157

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
/IP/	A1	WIPO	WO 93 20847	A	MINNESOTA MINING AND MANUFACTURING COMPANY	10-28-1998	Claims 1-27	
/IP/	A2	WIPO	WO 01 54719	A	SMITHKLINE BEECHAM BIOLOGIC. et al.	08-20-2001		
/IP/	A3	WIPO	WO 02 24225	A	GLAXO GROUP LIMITED	03-28-2002	Claim 25	
/IP/	A4	WIPO	WO 03 25003	A	BEATON ANDREW et al.	03-27-2003	Claims 1-27	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
/IP/	A5	BERNSTEIN, et al. "Effect of Imiquimod as an Adjuvant for Immunotherapy of Genital HSV in Guinea-Pigs." <i>Vaccine</i> (1995), vol. 13, no. 1, pp. 72-76.		
/IP/	A6	BILLAUT-MULOT, et al. "Modulation of Cellular and Humoral Immune Responses to a Multiepitopic HIV-1 DNA Vaccine by Interleukin-18 DNA Immunization/Viral Protein Boost." <i>Vaccine</i> , April 6, 2001, vol. 19, no. 20-22, pp. 2803-2811.		
/IP/	A7	VASILAKOS, et al. "Adjuvant Activities of Immune Response Modifier R-848: Comparison with CPG ODN." <i>Cellular Immunology</i> , August 25, 2000, vol. 204, no. 1, pp. 64-74.		

Examiner Signature	/Ileana Popa/	Date Considered	11/09/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.